This guideline will replace the “Note for guidance on the investigation of bioavailability and
bioequivalence" CPMP/EWP/QWP/1401/98 and the related questions in the Q&A document
(EMEA/CHMP/EWP/40326/2006). This guideline includes recommendations on BCS-based
biowaivers.